Delayed diagnosis and skipped nodal staging worsen penile cancer outcomes, according to Luis G. Medina, MD.
|Articles|June 1, 2003
PSA doubling of <3 months points to eventual death
Chicago-A post-treatment PSA doubling time less than 3 months followingeither surgery or radiation for localized or locally advanced prostate cancercan be a surrogate marker for eventual-perhaps inevitable-death from thedisease, according to data from a multicenter study of nearly 9,000 cancerpatients.
Advertisement
Advertisement
Related to this article
Butterfly Medical has also submitted a premarket approval application to the FDA.
Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Butterfly Prostatic Retraction Device granted EU MDR certification for BPH
3
Matching mCSPC treatment to the patient, not just the trial data
4
Timothy Clinton, MD, reviews bladder cancer data from 2026 AUA Northeastern Section Meeting
5